AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reyes, N.
Right arrow Articles by Hegde, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reyes, N.
Right arrow Articles by Hegde, S. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2005, p. 4344-4346, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4344-4346.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus

Noe Reyes, Robert Skinner, Koné Kaniga,{dagger} Kevin M. Krause, Josephine Shelton, Glenmar P. Obedencio, Alexander Gough, Michael Conner, and Sharath S. Hegde*

Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080

Received 17 March 2005/ Returned for modification 15 May 2005/ Accepted 6 July 2005

The efficacy of telavancin, a bactericidal lipoglycopeptide, was compared to that of vancomycin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) in a murine pneumonia model. Telavancin produced greater reductions in lung bacterial titer and mortality than did vancomycin and linezolid at human doses equivalent to those described by the area under the concentration-time curve. These results suggest the potential utility of telavancin for treatment of MRSA pneumonia.


* Corresponding author. Mailing address: Theravance, Inc., 901 Gateway Blvd., South San Francisco, CA 94087. Phone: (650) 808-6432. Fax: (650) 808-6441. E-mail: shegde{at}theravance.com.

{dagger} Present address: Peninsula Pharmaceuticals, Inc., 1900 Charleston Rd., Mountain View, Ca 94043.


Antimicrobial Agents and Chemotherapy, October 2005, p. 4344-4346, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4344-4346.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.